cyrilzakka/clinical-trials huggingface dataset:
The Research of Human Cortex Cell Atlas

In this study, the single-cell transcriptome sequencing technology was used to study the transcriptome differences at the single-cell level in normal human brain, aging human brain, and epileptic brain.

The human brain has about 100 billion cells and makes up neural networks.The abnormal activity of neurons can affect the operation of neural networks, leading to neurological diseases.With the coming of the age of global population aging, neurodegenerative diseases such as Alzheimer's, Parkinson's and Huntington's have become an increasing burden on human health.

Cells are the basic unit of brain. Understanding the mechanism of brain activities includes not only the mechanism of neural network, but also the self-regulation of its basic unit, that is, the regulation of gene expression based on brain activity.The abnormal expression and regulation of genes lead to the abnormal activities of the nervous system.Therefore, studying the regulation mechanism of gene expression at the cellular level is an important way to research brain diseases.The recent development of single-cell RNA-sequencing technology provides a possibility to understand the functioning mechanism of the brain at the cellular level.

Eligibility Criteria:
Inclusion Criteria:

* Craniocerebral injury patients needing operative treatment
* Treatment-resistant epilepsy patients needing resection surgery

Exclusion Criteria:

* Vital signs unstable
* Pregnancy
* Tumor
* Incomplete medical history, imaging and clinical diagnosis
A Phase 3 Study to Evaluate AZR-MD-001 in Patients with Abnormal Meibomian Gland Function and Dry Eye Disease (DED)

This study is a multicenter, double-masked, vehicle-controlled, randomized, parallel group study designed to evaluate the treatment of abnormal meibomian gland function and associated symptoms of DED using either AZR-MD-001 0.5% ophthalmic ointment or its vehicle. Study drug (either AZR-MD-001 or vehicle) will be dosed twice-weekly at bedtime for up to 12 months.

This study is designed to evaluate the treatment of abnormal meibomian gland function and associated symptoms of DED using either AZR-MD-001 0.5% ophthalmic ointment or its vehicle. Study drug (either AZR-MD-001 or vehicle) will be dosed twice-weekly at bedtime for up to 12 months.

Following a Screening qualification period, all patients diagnosed with abnormal meibomian gland function and associated symptoms of DED, and meeting the inclusion/exclusion criteria, will be randomized centrally, to treatment in a 1:1 ratio.

Study follow-up visits will be conducted on Day 14, Month 1.5, Month 3, Month 4.5, Month 6, Month 9, and Month 12. Patients will exit the study approximately 13 months after the Baseline visit. Any ongoing treatment-emergent adverse events (TEAEs) will be followed for an additional 30 days following the Month 12 visit.

Eligibility Criteria:
Inclusion Criteria:

* Male or female, 18 years of age or older at Screening.
* Evidence of active Evaporative DED at Screening and Baseline.
* Evidence of meibomian gland obstruction in both eyes at Screening and Baseline.

Exclusion Criteria:

* Ocular disease (except for Meibomian Gland Dysfunction (MGD) and DED/keratoconjunctivitis sicca) or systemic disease determined to be uncontrolled by the investigator.
* Patient has glaucoma, ocular hypertension, or an intraocular pressure (IOP) of ≥24 mm Hg in either eye at Screening.
* Recent (within the past 3 months of Screening) ocular surgery, trauma, herpes, or recurrent inflammation.
* Unwilling to abstain from the use of systemic or topical treatments for MGD or dry eye for the study duration.
Southeast Netherlands Advanced Metastatic Breast Cancer Registry

The Southeast Netherlands Advanced Breast Cancer (SONABRE) Registry is a real life multi-center study. The registry aims to include all patients diagnosed with advanced breast cancer as of 2007 in 11 hospitals in the Netherlands. Data on patient, tumor and treatment characteristics are collected retrospectively from electronic medical files by trained registry clerks.

This SONABRE registry is an ongoing observational cohort study aiming at the inclusion of all patients aged ≥18 years and diagnosed with advanced breast cancer since 2007 in 11 hospitals in the Southeast of the Netherlands. Patients with de novo or recurrent advanced breast cancer were identified from the hospital-based management information systems. Specially trained registration clerks retrospectively collected data from the medical files of the patients based on extensive medical chart review. Information was collected about patient and tumour characteristics, type of treatment (surgery, radiotherapy and systemic treatment, both neo-adjuvant, adjuvant and palliative), palliative treatment changes due to adverse events, hospitalization, comorbidities and outcomes (progression and death). The SONABRE Registry has already been effectively used to perform real-life studies on the use, safety and (cost-)effectiveness of various systemic treatments used in patients diagnosed with advanced breast cancer.

Eligibility Criteria:
Inclusion Criteria:

* Diagnosed with de novo or recurrent advanced breast cancer since 2007
* Diagnosed with or treated for advanced breast cancer in one of the participating hospitals
* Participating hospitals (period of inclusion): Maastricht UMC+ (2007-2025), Zuyderland hospitals Sittard/Heerlen (2007-2025), Amphia Hospital Breda (2013-2025), Catharina Hospital Eindhoven (2007-2025), Elkerliek Hospital Helmond (2010-2025), Maxima Medical Center Veldhoven/Eindhoven (2007-2025), Jeroen Bosch Hospital Den Bosch (2013-2025), Laurentius Hospital Roermond (2007-2025), St. Annaziekenhuis Geldrop (2007-2025), St. Elisabeth Hospital Tilburg (2007-2009), St. Jans Gasthuis Weert (2007-2025), VieCuri Medical Center Venlo/Venray (2013-2025), all in the Netherlands.
* Hospitals (and periods) were eligible for inclusion if (distant) registration from Maastricht UMC+ was possible.
* The inclusion period may be prolonged after 2025.

Exclusion Criteria: none
Caring for the Radial Artery Post-angiogram

The purpose of this pilot study was to compare two devices and three methods for achieving hemostasis after a transradial angiogram while assessing vascular complications and time endpoints. The heart has traditionally been accessed through the femoral artery. However, in the last 20 years, the radial artery has gained more popularity among physicians and patients, thereby offering an alternative to the femoral approach. Various methods of applying compression to the radial puncture site have been used, but no research has been done to show what best practice is. In this case, best practice would be the most effective way of getting hemostasis while limiting complications and ensuring the efficient use of nursing and medical resources. It is hypothesized that statistically significant differences are seen in time to discharge in the fast-release Terumo and Clo-Sur P.A.D. groups, as compared with the control Terumo group, without increasing vascular complications.


Eligibility Criteria:
Inclusion Criteria:

* nonemergent
* outpatient

Exclusion Criteria:

* inpatients
* emergency patients
* booked angioplasty patients
* cognitive impairment
* those in whom the approach was initiated but aborted due to inability to puncture the radial artery
Subjective Memory Complaints, Objective Memory Performance and Cognitive Training

The aim of this study is to examine if repetitive computerized cognitive training improves working memory in patients who are on sick leave due to complex symptom disorders (chronic pain, chronic fatigue, anxiety, depression and or sleep disorders), and whether effects of cognitive control training transfer to other tasks.


Eligibility Criteria:
Inclusion Criteria:

* on sick leave due to complex symptom disorders: chronic pain, chronic fatigue, anxiety, depression and/or sleep disorders
* on sick leave for at least eight weeks.

Exclusion Criteria:

* severe mental disorder
* acute psychosis
* ongoing manic episode
* suicidal ideation
* ongoing abuse of alcohol or any other substance.
* not able to communicate in Norwegian
Interaction Effects of Vitamin D Supplementation and Aerobic Exercises on Balance and Physical Performance in Children With Down Syndrome

Objective: To investigate the interaction effects of vitamin D supplementation and aerobic exercises on balance control and physical performance in children with Down syndrome (DS).

Methods: Forty-five children with DS ranging in age from 8 to 12 years will be selected and will participate in this study. They will be assigned randomly using sealed envelopes into three equal groups (A, B and C). Group A will consist of 15 children and will receive the conventional physical therapy program (CPTP) only. Group B will consist of 15 children and will receive the CPTP plus the aerobic exercises. Group C also will consist of 15 children and will receive the CPTP, the aerobic exercises and Vitamin D supplementation in the form of an oral dose of vitamin D3 1000 IU (Cholecalciferol). The program of treatment will be 3 days/week for 12 weeks. Evaluation of balance by using the biodex balance system and physical performance by using the six-minute walk test (6MWT) will be conducted at baseline and after 12 weeks of the treatment program.


Eligibility Criteria:
Inclusion Criteria:

* Children with DS who can stand and walk independently
* Children with 25 (OH) vitamin D levels of 16 ng/ml or less
* Children who are not consuming estrogens, steroids or other medications that could interfere with vitamin D metabolism
* The absence of visual and hearing impairments that could interfere with testing and training protocols
* Children with mild intellectual disabilities and were capable of understanding visual and verbal instructions.

Exclusion Criteria:

* Medical conditions that will severely limit a child's participation in the study as cardiac problems.
* Musculoskeletal deformities of the lower limbs.
Blood Levels of Local Anaesthetic in Knee Arthroplasty Using a Continuous Infusion Device

The primary goal is to evaluate ropivacaine blood concentrations during and after local anaesthetic (ropivacaine) infiltration - the Caledonian technique - for total knee replacement surgery. The investigators plan to measure these levels by testing blood samples taken over a timed period.

This will allow us to confirm whether the current regimen of local anaesthetic use is within safe limits.

Local anaesthetic (LA) toxicity may occur when the blood levels of a drug become particularly high. There is a need to confirm that the technique is safe to use. In addition, journal case reports may only describe serious side-effects of toxicity such as abnormal heart rhythms whilst more subtle clinical signs are rarely reported.

The investigators would like to study whether or not toxic levels may be approached in some patients or whether more subtle toxicity symptoms and signs are missed. For example, irregular heartbeat, low blood pressure or confusion/agitation.

Therefore, the investigators intend to study ropivacaine blood levels in patients receiving a total hip replacement in the Golden Jubilee National Hospital. A series of timed samples will be taken during the perioperative period. The anaesthesia and surgery will be performed as routine and no new treatment will be involved. Patient demographics, ropivacaine blood levels and clinical observations following LA administration will be collected.

Eligibility Criteria:
Inclusion Criteria:

* Male or female patients greater than 65 years of age

Exclusion Criteria:

* Patients with a known sensitivity/allergy to ropivacaine or amide-type local anaesthetics
* Patients who are not suitable for the Caledonian technique
* Patients who refuse or are unable to give consent
* Patients undergoing bilateral hip replacements
* Patients with known heart, liver or kidney failure
A Study of the Effect of Antibiotics on the Microbiology of the Bladder in Patients With Overactive Bladder

The concept of organisms living on or in the human body without causing overt signs of an infection is common in medicine and has been termed a microbiome. Urine from patients with Overactive bladder (OAB) grows different organisms from controls without OAB. However, it is not known if the bacteria that have been identified are innocent commensals or pathogenic organism responsible for the symptoms of OAB. Previous data suggests that treatment with antibiotics does lead to an improvement in overactive bladder symptoms in a large number of patients. On this basis the investigators now treat are patients with similar antibiotic regimes. If antibiotics improve symptoms it would be expected that they would return the microbiome back to how it is in patients without OAB. This study aims to identify the effects of antibiotics on the urinary microbiome and to identify/confirm if antibiotic treatments cause improvement in OAB.

This study is a consecutive cohort study. Subjects will be recruited from Urogynaecology clinics at Medway NHS Foundation Trust. Patients will be identified from previous records and also prospectively from new patients. They will be sent information regarding the trial before attending their first appointment.

Patients attending urogynaecology clinics will provide a fresh clean catch specimen of urine. A conventional hospital Mid stream speciemn of urine (MSU) will be sent. Urine will be dipsticked for nitrites and leucocyte esterase. The urine will then be spun and undergo microscopy using a special stain (looking for intracellular organisms in shed urothelial cells). The urothelial cells will be cleaned with antibiotics. The cells will then be lysed and their contents cultured. The contents will undergo Polymerase Chain Reaction (PCR) sequencing to identify bacteria. Sensitivity testing will be used to assess and deliver the appropriate antibiotic regime.

Women will be treated with a 6 week course of antibiotics as per their usual treatment. Broad spectrum antibiotics will be prescribed to all women based on the previous successful therapeutic regime as described by Vijaya. Six weeks after the end of antibiotic therapy patients will be reviewed and their urine retested.

Eligibility Criteria:
Inclusion Criteria:

1. \> age 18 years
2. Negative urine dipstick (nitrites) and culture (x10 to the power 5 colony forming units) x105 cfu
3. Idiopathic overactive bladder as per International Continence Society definition

Exclusion Criteria:

1. Patients treated with antibiotics for any infection within the last 6 weeks.
2. Patients with known multiple sclerosis, stroke, spinal injury, or other neurological disease
3. Urinary tract infection diagnosed by nitrite positivity or positive urine culture (x105 cfu)
4. Undiagnosed macroscopic or persistent microscopic haematuria needing investigation
5. Previous or current cancer of the urogenital tract.
6. Contraindication to multiple antibiotics
7. No suitable oral antibiotic regime
8. Patients unable to understand the study or complete the questionnaires.
On-Line Intervention For Promoting Healthy Habits And Weight Loss In Hypertensive Patients

Efficacy of an Internet-based self-guided intervention for promoting healthy habits and weight loss in hypertensive people with overweight and obesity: A Randomized Controlled Trial

The prevalence of overweight and obesity is on the rise worldwide with severe physical and psychosocial consequences. Hypertension is one of the comorbidities associated with obesity. Changes in lifestyles through eating behavior and physical activity level are the critical components in the prevention and treatment for hypertension and obesity. Data from several studies indicate that the usual procedures to promote these healthy habits in health services are inadequate. ICTs has been demonstrated as an effective tool for implementation of psychological interventions focused on this type of population. This study aims to describe a totally self-applied online program (¨Vivir Mejor¨) to promote healthy lifestyles (eating behavior and physical activity) for obese participants with hypertension. Participants (BMI=25-35) will be recruited from users of a hypertension unit of a public hospital and will be randomized into two groups: experimental group "Vivir Mejor" and control group (treatment as usual). "Vivir Mejor" program is composed by 9 modules aimed for promoting healthy eating habits and increase physical activity. Modules will be sent via Internet periodically. After 6 months, a follow-up testing phase and a tracking module will be set. The outcomes variables will include anthropometric data, changes in eating behavior and physical performance and cardiovascular variables.

Eligibility Criteria:
Inclusion Criteria:

* Overweight or obese grade I (BMI\> 25 and \<35)
* Age between 18-65 years
* Being in clinical medical treatment for prevention of metabolic syndrome or Cardiac complications
* Having internet access.

Exclusion Criteria:

* No Internet access; Taking more than 3 antihypertensive drugs
* Have Diabetes diagnosis; Meet the DSM-IV-TR of Eating Disorder
* Submit a serious psychological disorder diagnosed (psychosis, bipolar disorder, major depressive disorder, substance abuse)
* Have a disability which prevents or hinders the exercise and physical activity
* Be receiving any treatment for weight loss in another center.
A Study of LY3549492 in Japanese Participants With Type 2 Diabetes Mellitus (T2D) and Healthy Japanese Participants

The purpose of this study is to evaluate how well LY3549492 is tolerated and what side effects may occur in Japanese participants with Type 2 Diabetes Mellitus (T2D) and healthy Japanese participants. The study drug will be administered orally. Blood tests will be performed to check how much LY3549492 gets into the bloodstream and how long it takes the body to eliminate it.

The study will last up to approximately 19 weeks for both Part A (Cohorts 1-3) for multiple-ascending doses (MAD), and Part B (Cohorts 4-5) multiple-ascending doses (MAD), for a total of approximately 25 weeks, including screening.


Eligibility Criteria:
Inclusion Criteria:

Part A:

* Participants with T2DM for at least 6 months
* With an HbA1c value:

  * equal to or greater than 7.0% and equal to or less than 10.0% at screening for participants treated with diet and exercise alone, OR
  * equal to or greater than 6.5% and equal to or less than 9.0% for participants prior to washout of antidiabetic medications
* Have had a stable weight for the 3 months prior to screening. Stable weight is defined as less than 5% body weight change

Part B:

* Have safety laboratory test results within normal reference range for the population or investigative site, or results with acceptable deviations that are judged to be not clinically significant by the investigator. Laboratory tests may be repeated if there is a documented technical error, or once at the discretion of the investigator for any out-of-range results

Exclusion Criteria:

* Have a known clinically significant gastric emptying abnormality
* Have a 12-lead electrocardiogram (ECG) abnormality
* Have an abnormal blood pressure or pulse rate
* Have a significant history within the past 6 months or current evidence of comorbidities capable of altering the absorption, metabolism, or elimination of drug. Or constituting a risk when taking the study drug
* Have a history of chronic medical conditions involving the heart, liver, or kidneys
Safety of Larazotide Acetate in Healthy Volunteers

To demonstrate the safety, tolerance and pharmacokinetics of multiple, oral doses of larazotide acetate.

CLIN1001-003 was a Phase 1, randomized, double-blind, placebo controlled multi-dose study to determine the safety, tolerance, and pharmacokinetics (including food effect) of 3 dose levels of larazotide acetate in healthy volunteers. Three (3) cohorts of 8 subjects, in which six (6) subjects in each cohort received larazotide acetate in escalating doses of 0.25 mg, 1 mg, or 4 mg TID for 10 days and two (2) subjects received placebo TID for 10 days, were studied. Subjects maintained a standard gluten-free diet. Subjects were dosed three times a day 30 minutes prior to meals except for the morning dosing on Days 1, 5, and 10. For the morning dosing on Days 1, 5, and 10 subjects, fasted overnight prior to dosing and for 2 hours post dose. Subjects were evaluated for safety (medical history, physical examination, vital signs, clinical laboratory testing, and 12-lead electrocardiograms) throughout the study. Serial blood samples were collected or pharmacokinetic determinations at baseline and 2 hours post morning dose on Days 1, 2, 5, 6 and 10.

Eligibility Criteria:
Inclusion Criteria:

* Healthy male and female subjects
* BMI between 18 and 30.

Exclusion Criteria:

* Subjects with clinically significant abnormal clinical lab results
* Hemoglobin \< 12g/dL
* Subjects with diarrhea within 3 days prior to treatment visit
Prevention of Pacemaker Lead Induced Tricuspid regurgitAtion by Transesophageal eCho guidEd Implantation Registry

Registry for patients undergoing pacemaker/ICD implantation including a transtricuspid lead with and without intraprocedural transesophageal echocardiography to evaluate risk factors for lead induced tricuspid regurgitation.

Lead induced tricuspid regurgitation is a common finding after pacemaker/ICD Implantation. Transesophageal echocardiography (TEE) might be used to guide lead implantations in order to prevent tricuspid regurgitation.

In this registry, patients undergoing pacemaker/ICD implantation including a transtricuspid lead are enrolled. While in most patients lead implantation is guided by fluroscopy, in some patients lead implantation is guided by TEE in addition to fluroscopy.

Aims of this registry: Evaluation of

* Incidence of lead induced tricuspid regurgitation
* Mortality and morbidity of lead induced tricuspid regurgitation
* Identification of risk factors for lead induced tricuspid regurgitation
* Influence of the lead position within the tricuspid valve on the incidence of lead induced tricuspid regurgitation
* Prevention of lead induced tricuspid regurgitation by TEE-guided lead implantation

Eligibility Criteria:
Inclusion Criteria:

* indication for pacemaker/ICD implantation including a transtricuspid lead according to guidelines

Exclusion Criteria:

* pre-existing RV lead
* pre-existing TR \>2
MATCh Parents' Supplemental Survey

Primary Objectives:

1. To collect data on health behaviors in the parents of MATCh study participants
2. To collect and/or update risk factor data from the parents of the MATCh study participants.

This research project is for the parents of study participants in the "Predictors of Smoking in Mexican American Youth," also known as the MATCh study.

This research project has three objectives.

These include:

1. collecting data on your health behaviors. Researchers are interested in this information because your health behaviors may influence your children's health behavior;
2. learning about the types of interventions that would be of most use and interest to you and your family; and
3. learning about the most convenient and useful way in which these interventions would be delivered.

Researchers are interested in knowing about the types of interventions that would benefit you and your family because they would like to design future intervention studies that meet your needs and the needs others in your community.

Eligibility Criteria:
Inclusion Criteria:

1. The parent or legal guardian of the child participating in UT MDACC Protocol 2004-0616. Parents/legal guardians will be identified and enrolled after their child is enrolled in protocol 2004-0616.
2. Participants who speak English, Spanish or are bilingual are eligible to participate.

Exclusion Criteria: None